Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on the day's biggest business stories
Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Illustration: Sarah Grillo/Axios
The race for a COVID-19 vaccine is ramping up, with three major candidates now reporting efficacy rates of more than 90%.
Why it matters: Health experts say the world can't fully return to normal until a coronavirus vaccine is widely distributed. But each potential vaccine has its own nuances, and it's likely that multiple vaccines will be needed in order to supply enough doses for universal vaccination.
- Some global vaccines have been approved for limited distribution, including vaccines in China and Russia that did not wait for Phase 3 results before authorization. Public health authorities warn skipping steps could pose serious risks.
- No vaccines have been approved for full use.
Major candidates
Pfizer-BioNTech:
- Efficacy: 95%
- Vaccine type: mRNA
- Doses required: 2
- Storage: Five days in a refrigerator or -70℃ for long-term storage
- Manufacturing: Up to 50 million doses in 2020 and 1.3 billion in 2021, per Pfizer
- Cost: $20 per dose
- State of play: Pfizer has applied for an emergency use authorization (EUA) from the FDA.
Moderna:
- Efficacy: 94.1%
- Vaccine type: mRNA
- Doses required: 2
- Storage: 30 days in the refrigerator or six months at -20℃
- Manufacturing: 20 million in 2020 and up to 1 billion in 2021, per Moderna
- Cost: $32-37
- State of play: Moderna said it would apply for an EUA on Nov. 30
Oxford-AstraZeneca:
- Efficacy: 62% to 90%, depending on dosage (average 70.4%)
- Vaccine type: Combination of common cold virus and coronavirus genetic material
- Doses required: 1.5
- Storage: Six months in the refrigerator
- Manufacturing: Total annual capacity of 3 billion doses, per AstraZeneca
- Cost: $3-4